Indisulam
| Title | Journal |
|---|---|
| Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety. | Bioorganic & medicinal chemistry 20131001 |
| Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment. | Cancer chemotherapy and pharmacology 20120501 |
| Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target. | Journal of medicinal chemistry 20120412 |
| Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana. | Bioorganic & medicinal chemistry 20120215 |
| Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. | Investigational new drugs 20111001 |
| Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives. | European journal of medicinal chemistry 20110901 |
| Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. | Bioorganic & medicinal chemistry 20110815 |
| A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. | Bioorganic & medicinal chemistry 20110201 |
| Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata. | Bioorganic & medicinal chemistry letters 20110115 |
| Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII. | European journal of medicinal chemistry 20100901 |
| New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors. | Bioorganic & medicinal chemistry letters 20100615 |
| Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides. | European journal of medicinal chemistry 20100601 |
| Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis. | Journal of medicinal chemistry 20100311 |
| Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. | Investigational new drugs 20100201 |
| Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c. | Bioorganic & medicinal chemistry letters 20091201 |
| Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. | Bioorganic & medicinal chemistry 20090715 |
| Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. | Journal of medicinal chemistry 20090709 |
| Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. | Bioorganic & medicinal chemistry 20090701 |
| Self-associated indisulam in phospholipid-based nanomicelles: a potential nanomedicine for cancer. | Nanomedicine : nanotechnology, biology, and medicine 20090601 |
| Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis. | Journal of medicinal chemistry 20090514 |
| Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate. | Journal of medicinal chemistry 20090423 |
| Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates. | Bioorganic & medicinal chemistry 20090201 |
| Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. | Journal of pharmacokinetics and pharmacodynamics 20090201 |
| Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. | British journal of clinical pharmacology 20081001 |
| Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes. | Bioorganic & medicinal chemistry letters 20080615 |
| Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. | Journal of medicinal chemistry 20080612 |
| PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. | Clinical pharmacology and therapeutics 20080601 |
| Development of small molecule carbonic anhydrase IX inhibitors. | BJU international 20080601 |
| A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. | British journal of cancer 20080422 |
| Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. | Bioorganic & medicinal chemistry 20080401 |
| Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. | Journal of medicinal chemistry 20080327 |
| Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. | Bioorganic & medicinal chemistry 20071201 |
| Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070). | Melanoma research 20071001 |
| Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. | Bioorganic & medicinal chemistry letters 20070701 |
| CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070515 |
| Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. | Journal of medicinal chemistry 20070405 |
| Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. | Bioorganic & medicinal chemistry letters 20070315 |
| A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070315 |
| A phase I and pharmacokinetic study of indisulam in combination with carboplatin. | British journal of cancer 20070226 |
| Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. | Journal of medicinal chemistry 20070125 |
| A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by 'click-tailing'. | Journal of medicinal chemistry 20061102 |
| Targeting tumor-associated carbonic anhydrase IX in cancer therapy. | Trends in pharmacological sciences 20061101 |
| A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam. | Journal of pharmacokinetics and pharmacodynamics 20061001 |
| Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. | Journal of medicinal chemistry 20060907 |
| Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. | Drug metabolism and disposition: the biological fate of chemicals 20060601 |
| Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori. | Bioorganic & medicinal chemistry letters 20060415 |
| Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. | Journal of medicinal chemistry 20060323 |
| Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. | Journal of medicinal chemistry 20051201 |
| Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with benzo[b]thiophene 1,1-dioxide sulfonamides. | Bioorganic & medicinal chemistry letters 20051101 |
| Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. | Cancer science 20051001 |
| Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. | Journal of medicinal chemistry 20050908 |
| Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. | Investigational new drugs 20050801 |
| Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. | Journal of medicinal chemistry 20050728 |
| Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. | Bioorganic & medicinal chemistry letters 20050615 |
| Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. | Bioorganic & medicinal chemistry letters 20050615 |
| Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. | Investigational new drugs 20050601 |
| Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. | Bioorganic & medicinal chemistry letters 20050502 |
| Drugging cell cycle kinases in cancer therapy. | Current drug targets 20050501 |
| Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. | Bioorganic & medicinal chemistry letters 20050201 |
| Phase II study of E7070 in patients with metastatic melanoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20050101 |
| Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. | Bioorganic & medicinal chemistry letters 20041206 |
| Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. | Bioorganic & medicinal chemistry letters 20041101 |
| A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040715 |
| Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. | Bioorganic & medicinal chemistry letters 20040503 |
| Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. | Journal of medicinal chemistry 20040422 |
| Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. | Investigational new drugs 20040401 |
| Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. | Bioorganic & medicinal chemistry letters 20040223 |
| Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. | Bioorganic & medicinal chemistry letters 20040119 |
| Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. | Bioorganic & medicinal chemistry letters 20040105 |
| Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20040101 |
| Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031101 |
| In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. | Anti-cancer drugs 20030701 |
| Quantitative chemical proteomics for identifying candidate drug targets. | Analytical chemistry 20030501 |
| Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). | European journal of cancer (Oxford, England : 1990) 20030501 |
| New analogues of the anticancer E7070: synthesis and pharmacology. | Journal of enzyme inhibition and medicinal chemistry 20030401 |
| Indisulam: an anticancer sulfonamide in clinical development. | Expert opinion on investigational drugs 20030201 |
| E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. | Anti-cancer drugs 20021101 |
| Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide). | British journal of clinical pharmacology 20021101 |
| Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. | Journal of medicinal chemistry 20021024 |
| Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021001 |
| An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. | Anti-cancer drugs 20020901 |
| Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020815 |
| Anticancer agent E7070 inhibits amino acid and uracil transport in fission yeast. | Molecular pharmacology 20011201 |
| E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. | European journal of cancer (Oxford, England : 1990) 20011101 |
| Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). | Annals of oncology : official journal of the European Society for Medical Oncology 20010901 |
| Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. | Investigational new drugs 20010101 |